Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2019.02.031
Abstract: To the Editor: Secukinumab, an interleukin 17A inhibitor approved for the treatment of moderate-tosevere plaque psoriasis, has shown high levels of clinical efficacy and a favorable safety profile in both short-term and long-term clinical trials.… read more here.
Keywords: drug survival; study; drug; secukinumab drug ... See more keywords
THU0327 Real world (RW) experience with an anti-il-17a inhibitor in biologic naÏve and biologic experienced psoriatic arthritis (PSA) patients
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.7341
Abstract: Background Two IL-17A inhibitors are approved for the treatment of PsA, ixekizumab and secukinumab. At the time of this survey, real world evidence was only available for secukinumab, which was approved for PsA in 2016… read more here.
Keywords: real world; biologic; psa patients; biologic experienced ... See more keywords